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Genetic models have shown that distinct
signaling pathways modulate spec-
ification, patterning, and remodeling of
lymphangiogenesis and angiogenesis
during embryonic development. However,
the precise identity of cellular and molecu-
lar pathways that maintain the integrity
and remodeling of the lymphatic and blood
vessels postnatally are complex, and
these processes are most likely driven by
the collaboration of various organ-specific
angiogenic and lymphangiogenic factors.
VEGF-A, through interactions with its cog-
nate receptors VEGFR-1 and VEGFR-2,
supports vasculogenesis and angiogene-
sis (Carmeliet and Jain, 2000), while
VEGF-C and VEGF-D through interaction
with VEGFR-3 primarily support lymphan-
giogenesis (Alitalo and Carmeliet, 2002).
However, angiogenic factors, including
fibroblast growth factor-2 (FGF-2), and
angiopoietins, which were previously
thought to exclusively regulate angiogene-
sis, have also been shown to contribute to
the remodeling of lymphatic vessels. In
line with these new discoveries, in this
issue of Cancer Cell, Cao et al. (2004) pro-
vide provocative evidence suggesting that
the PDGF/PDGF-receptor signaling path-
way may not only be important for support-
ing angiogenesis, but also for promoting
tumor lymphangiogenesis independent of
VEGFR-3 signaling.This finding sets forth
the concept that under certain conditions,
vascular growth factors, such as PDGF,
may have overlapping functions not only
supporting postnatally driven neoangio-
genic but also organ-specific lymphangio-
genic processes.
It is now well established that VEGF-
C and VEGF-D, through interaction with
their tyrosine kinase receptor, VEGFR-3,
support differentiation and patterning of
Prox-1+ endothelial cells into lymphatic
vasculature (Alitalo and Carmeliet, 2002;
Karkkainen et al., 2004). Targeted inacti-
vation of VEGFR-3 results in embryonic
lethality as a result of failure to remodel
the primary capillary plexus into a more
mature lymphatic vascular network.
Later, however, expression of VEGFR-3
is downregulated in blood vessels and
becomes restricted to the lymphatic
endothelial cells, which sprout from
embryonic veins and start to form primi-
tive lymph sacs. In adult tissues,
VEGFR-3 is expressed primarily in the
lymphatic vasculature and in some fen-
estrated blood vessel endothelia. VEGF-
C/VEGFR-3 pathway is activated in the
blood vessels of certain tumors and
plays a role in mediating tumor lymphan-
giogenesis and lymph node metastasis
(Mandriota et al., 2001; Stacker et al.,
2002).
In addition to VEGFR-3 signaling,
other signaling pathways, including
angiopoietin/Tie2 and FGF-2, have
been shown to play a role in remodeling
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Vascular frontiers without borders: Multifaceted roles of platelet-
derived growth factor (PDGF) in supporting postnatal
angiogenesis and lymphangiogenesis
The platelet-derived growth factor (PDGF) family of growth factors, which primarily serves the function of stabilizing
vascular networks, has now been shown to play a role in promoting tumor lymphangiogenesis. PDGF-BB, independent of
VEGFR-3 signaling, induces tumor growth and metastasis in part through supporting lymphangiogenesis. These data
suggest that targeting the PDGF/PDGF-receptor signaling pathway will provide a novel strategy to block tumor
neoangiogenesis and lymphangiogenesis, thereby inhibiting tumor growth and metastasis.
Figure 1. The crosstalk between vascular net-
work stabilization and induction of lymphan-
giogenesis is modulated by the PDGF/PDGFR
signaling pathway
VEGF-C and VEGF-D, through interaction with
their tyrosine kinase receptor VEGFR-3, sup-
port the development, specification, and
maintenance of lymphatic vessel postnatally.
VEGF-C/VEGF-D/VEGFR-3 signaling induces
Prox-1 expression in endothelial cells, which
become committed to lymphatic endothelial
cells. PDGF recruits mural cells to coat
nascent vessels essential for the stabilization
and further establishment of the vascular net-
work. PDGF, by recruiting PDGFR+ lymphatic
endothelial cells, induces lymphangiogenesis
and lymphatic tumor growth and metastasis
through a VEGFR-3- and Prox-1-independent
pathway. Lymphatic vessels would then pro-
vide the channels for tumor spread to the
lymph nodes, and blood vessels would pro-
vide a conduit for tumor metastasis to distant
organs.
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of lymphatic vessels. Angiopoietin-2-
deficient mice form lymphatic vessels
but have profound defects in lymphatic
vessel remodeling, resulting in chylous
ascites and defects in pattering and
function of lymphatic vasculature (Gale
et al., 2002). FGF-2 at low doses
induces VEGF-C and VEGF-D expres-
sion and promotes lymphangiogenesis
through activation of VEGFR-3 signal-
ing (Chang et al., 2004; Kubo et al.,
2002). In addition, expression of SLP-
76 and Syk signaling proteins is impor-
tant for the separation of the lymphatic
and blood vessels (Abtahian et al.,
2003). These data suggest that,
although the VEGF-C/VEGF-D/VEGFR-
3 signaling pathway is absolutely
essential for the initial embryonic devel-
opment of lymphatic vessels, other 
signaling pathways may modulate pat-
terning and remodeling of the lymph-
angiogenesis in a context-dependent
manner. In this regard, the data pre-
sented by Cao et al. (2004) suggest that
PDGF/PDGFR signaling may also play
a critical role in modulating lymphangio-
genesis in specific pathophysiological
conditions, such as organ-specific
tumor growth.
Cao et al. (2004) demonstrate that
PDGF-BB can induce intratumoral lym-
phangiogenesis and lymphatic metastasis
by a VEGFR-3-independent mechanism
(Figure 1). They report that expression of
PDGF-BB in murine fibrosarcoma cells
induced tumor lymphangiogenesis, lead-
ing to enhanced metastasis in lymph
nodes. In addition, they demonstrate that
PDGFRs are expressed on newly lym-
phatic cells and that PDGF-BB is a potent
activator of lymphatic endothelial cell
motility. Inhibition of VEGFR-3 did not
block PDGF-BB-induced lymphangiogen-
esis.These data suggest that PDGFs may
modulate the postnatal remodeling of lym-
phatic vessels, but not development of
rudimentary lymphatic vessels.
Expression of the Prox-1 is essential
for VEGF-C/VEGFR-3-mediated initiation
and specification of lymphangiogenesis
during embryonic development (Oliver
and Detmar, 2002). However, PDGFs did
not require Prox-1 activation to induce
lymphangiogenesis. The finding by Cao
et al. that PDGFs support lymphangio-
genesis independent of Prox-1 has sev-
eral implications. It is possible that
PDGF/PDGFR signaling is not critical for
the Prox-1 dependent developmental
generation of the lymphatic vessels.
Alternatively, PDGFs, through activation
of an as yet unrecognized signaling
pathway(s), support lymphangiogenesis
during specific pathophysiological
conditions.
This unexpected function of PDGF
in the regulation of lymphangiogenesis
comes as a surprise, since most of
transgenic models and in vitro studies
had suggested that PDGFs primarily
modulate vascular development and
stabilization (Betsholtz, 2004). PDGF
was purified as a factor from platelets
that promote the proliferation of mes-
enchymal cells. Five members constitute
the complete PDGF family: AA, BB, 
AB, CC, and DD (Betsholtz, 2004).
Processes driven by the PDGFRs
include angiogenic sprouting and
branching of vascular endothelium.
PDGF released by endothelial or other
cell types triggers pericyte recruitment
to coat nascent vessels, which is essen-
tial for the stabilization and further
establishment of the vascular network
(Lindblom et al., 2003). Although no
studies so far have demonstrated antitu-
mor effects of targeting PDGF alone, the
well-documented effect of PDGF on per-
icyte and tumor stroma recruitment
(Dong et al., 2004) points to the possibil-
ity that PDGF may collaborate with other
angiogenic factors to support tumor
angiogenesis as well as lymphangio-
genesis.
Cao et al. (2004) demonstrate that
PDGFR-β is expressed on lymphatic
endothelial cells conveying signals that
support migration and survival of these
cells. Therefore, PDGF-BB may induce
lymphangiogenesis directly by recruit-
ing and remodeling of PDGFR-β+ lym-
phatic endothelial cells, thereby
supporting tumor growth and metasta-
sis. One other mechanism by which
PDGFs, including the newly discovered
PDGF-D, may regulate both neoangio-
genesis and lymphangiogenesis, is
through recruitment of proangiogenic
myeloid cells (Uutela et al., 2004).
Subsets of hematopoietic cells are
recruited to the ischemic niche where,
by releasing paracrine factors, they sup-
port neoangiogenesis or lymphangio-
genesis (Schoppmann et al., 2002).
Similarly, PDGF-BB, through recruit-
ment of myeloid cells, may support the
assembly of stable blood neovessels
and contributes to the remodeling of the
lymphatic vessels.
The study by Cao et al. has also
raised several major unresolved issues.
It remains to be determined whether
PDGFs exert their effect on lymphangio-
genesis exclusively through PDGFR sig-
naling. Although soluble VEGFR-3 or
neutralizing antibodies to VEGFR-3
failed to block PDGF-BB-mediated lym-
phangiogenesis, it is still possible that
PDGFR autophosphorylation through
inside-inside intracellular activation of
VEGFR-3 tyrosine kinase may induce
neoangiogenesis. The effect of PDGF-
BB in modulating lymphangiogenesis 
in VEGFR-3 deficient mice will also
determine whether PDGFs may promote
lymphangiogenesis independent of
VEGFR-3 signaling or through overlap-
ping signaling cascades. In addition, it is
important to examine PDGFR-β and
PDGFR-α knockout mice for potential
lymphangiogenic defects. Although the
edema observed in PDGFR-β knockout
mice is primarily due to defective pericyt-
ic investment of the newly formed
vessels, it is possible that subtle lym-
phangiogenic defects may also con-
tribute to the generation of edema in
these mice. Finally, preliminary clinical
evidence that certain antibodies to
PDGFRs given to patients with
advanced solid tumors may induce
edema suggests that PDGFs may not
only be important for vessel stability, but
that they may also support lymphatic
vessel integrity.
Although the VEGFR-3 signaling
pathway controls many important aspects
of lymphatic vasculature growth, accumu-
lating evidence suggests that other play-
ers, such as angiopoietins, FGFs, and
now PDGF/PDGFR, are involved in gener-
ating and remodeling of lymphatic vascu-
lature. Whether organ-specific expression
of PDGF or angiopoietins collaborates
with VEGF-C/VEGFR-3 pathways to
induce lymphangiogenesis remains to be
determined. Nonetheless, the data pre-
sented by Cao et al. highlight the signifi-
cance of the PDGF family in regulating
angiogenesis and lymphangiogenesis.
Monotherapy with PDGFR inhibitors
seems to be ineffective in blocking tumor
growth. On the other hand, PDGF antago-
nists combined with chemotherapy have
been more effective in blocking tumor
growth (Pietras et al., 2002). As such, 
targeting PDGF in conjunction with
chemotherapeutic agents will provide for
an effective means to block tumor growth
and metastasis.
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When faced with an increased threshold
of oncogenic signals that provoke cells to
divide at an abnormally accelerated
pace, the Arf tumor suppressor gene is
activated. Its encoded product (p19Arf in
mouse or p14ARF in humans) antagonizes
the ubiquitin E3 protein ligase activity of
the p53 negative regulator Mdm2 (Hdm2
in humans) to trigger a p53-dependent
transcriptional response that leads to
either cell cycle arrest or apoptosis.
These protective responses can be dis-
abled through deletion or silencing of Arf,
by generation of dominant-negative
mutants of p53, or through mechanisms
leading to Mdm2 overexpression, so
enabling incipient cancer cells to thrive.
Myc was the first oncogene recog-
nized to activate Arf gene expression
(Zindy et al., 1998), although the mecha-
nism by which it does so remains unclear.
When Myc expression is enforced in
mouse B-lymphocytes in vivo, its enhanc-
ing effects on cell proliferation are inhibit-
ed by the Arf-Mdm2-p53 axis, but dis-
abling the pathway cancels Myc-induced
apoptosis and allows formation of B cell
lymphomas (Eischen et al., 1999).
Observations that Myc could trigger a p53
response through the agency of Arf were
conceptually satisfying, but additional
complexities soon became apparent.
First, high and sustained Myc activity is
required for Arf induction, but the promot-
er is normally insulated from responding
to physiologic Myc signals. Second, cells
lacking p53 or harboring mutant forms of
the protein display dramatic upregulation
of p19Arf, and reintroduction of p53
represses Arf transcription. This feedback
control by p53 also extends to c-Myc,
again through an unknown mechanism
(Figure 1). Most importantly, however,
mice engineered to lack both Arf and p53,
or all three genes in the pathway, develop
(usually multiple) cancers at a faster rate,
and the spectrum of tumor types arising in
these mice is much broader than that of
animals lacking either Arf or p53, or both
Mdm2 and p53, providing genetic evi-
dence that p19Arf must have p53-indepen-
dent functions (Weber et al., 2000).
Indeed, cells lacking Arf and p53 prolifer-
ate faster than those lacking either gene
alone, and enforced overexpression of Arf
can arrest the proliferation of p53 null
mouse embryo fibroblasts (MEFs), albeit
inefficiently (Eischen et al., 1999; Weber
et al., 2000).
Recent studies now suggest that
p19Arf can negatively regulate Myc’s tran-
scriptional activity through a direct physi-
cal interaction that is seemingly
independent of Mdm2 and p53 (Qi et al.,
2004). These investigators report some
surprising findings that include Myc’s abil-
ity to bind directly to Arf and to relocalize
Arf from its usual storehouse in the nucle-
olus into the nucleoplasm in both wild-
type and p53-deficient MEFs. Most
striking, however, are their observations
that p19Arf associates with Myc on its tar-
Antagonism of Myc functions by Arf
The Arf-Mdm2-p53 tumor suppressor pathway is activated by sustained hyperproliferative signals emanating from onco-
proteins such as Myc. A recent study reveals a novel level of feedback control, whereby induced p19Arf binds to Myc and
blocks cell proliferation by selectively impairing its transactivation functions.
